The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 29, 2020

Filed:

Jan. 07, 2019
Applicant:

National University Corporation Tokyo Medical and Dental University, Tokyo, JP;

Inventors:

Johji Inazawa, Tokyo, JP;

Jun Inoue, Tokyo, JP;

Shinsuke Yamamoto, Tokyo, JP;

Tatsuyuki Kawano, Tokyo, JP;

Ken-ichi Kozaki, Tokyo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/713 (2006.01); G01N 33/50 (2006.01); A61K 33/24 (2019.01); A61K 45/06 (2006.01); A61K 33/243 (2019.01); A61K 48/00 (2006.01); A61K 31/7088 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 33/24 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); G01N 33/5011 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2320/30 (2013.01); C12N 2320/31 (2013.01);
Abstract

The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.


Find Patent Forward Citations

Inazawa, Johji. (2020). Method for assaying microrna, cancer therapeutic agent, and medical composition containing same for cancer therapy (U.S. Patent No. 10876115). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10876115

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…